Who are Luveris's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ovidrel, Zoladex, Cetrotide, Ovidrel, Ovitrelle, Orgovyx.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/r-hlh.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Luveris — Competitive Intelligence Brief

Luveris (r-hLH) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin. Area: Other.

marketed Gonadotropin Lutropin-choriogonadotropic hormone receptor Other Small molecule Live · refreshed every 30 min

Target snapshot

Luveris (r-hLH) — Merck KGaA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Luveris TARGET	r-hLH	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2004-01-01
Ovidrel	CHORIOGONADOTROPIN ALFA	Merck KGaA	marketed	Gonadotropin	Lutropin-choriogonadotropic hormone receptor	2000-01-01
Zoladex	Zoladex	University of Michigan Rogel Cancer Center	marketed		Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor
Cetrotide	Cetrotide	Wolfson Medical Center	marketed		Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor
Ovidrel	Ovidrel	Nanjing University	marketed		Lutropin-choriogonadotropic hormone receptor
Ovitrelle	Ovitrelle	Hadassah Medical Organization	marketed		Lutropin-choriogonadotropic hormone receptor
Orgovyx	relugolix	MYOVANT SCIENCES	marketed	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	Gonadotropin-releasing hormone receptor	2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-02-25 — Orgovyx · 10350170 · US
2037-09-29 — Orgovyx · 10449191 · US
2037-09-29 — Orgovyx · 11583526 · US
2037-09-29 — Orgovyx · 11033551 · US
2037-09-29 — Orgovyx · 10786501 · US

Sponsor landscape (Gonadotropin class)

Instituto Valenciano de Infertilidad, IVI VALENCIA · 4 drugs in this class
Sisli Hamidiye Etfal Training and Research Hospital · 3 drugs in this class
Organon and Co · 3 drugs in this class
Fundación Santiago Dexeus Font · 3 drugs in this class
Merck KGaA · 2 drugs in this class
Nina la Cour Freiesleben · 2 drugs in this class
IVI Madrid · 2 drugs in this class
Dunamenti REK Istenhegyi IVF Center · 1 drug in this class
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 drug in this class
Azienda USL Modena · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Luveris — Competitive Intelligence Brief. https://druglandscape.com/ci/r-hlh. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab